^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Epi proLung®

    Company:
    Epigenomics
    Type:
    CE Marked
    Related tests:
    Details
    Evidence

    News

    2d
    Decoding the SHOX2 Methylation-Expression Paradox in Lung Adenocarcinoma: Dual-Regulatory Methylation Patterns Drive Oncogenic Activation and Prognostic Relevance. (PubMed, Cancer Lett)
    Our findings redefine epigenetic regulation in LUAD, demonstrating that regional methylation patterns-not global promoter status-orchestrate oncogene activation. We propose a novel framework for spatially resolved methylomics, advocating 1) dual-target assays monitoring both promoter and gene body methylation to improve diagnostic precision, and 2) therapeutic exploitation of SHOX2's intronic methylome as a druggable epigenetic switch.
    Journal
    |
    SHOX2 (SHOX Homeobox 2)
    |
    Epi proLung®
    |
    Intron A (interferon α-2b)